New Treatment Regimen Offers Promise for Rare Lymphoma
By studying a common virus and a rare cancer, Ohio State researchers have developed a treatment that could improve outcomes for some lymphoma patients.
A new treatment regimen developed at the OSUCCC – James may offer promising results for a rare form of lymphoma courtesy of therapies for the Epstein-Barr virus – a virus carried by more than 90 percent of people.
Through the administration of those anti-viral medicines, researchers found that they could “program” CNS lymphoma cells to self-destruct.
“Thus far, 23 patients have been treated, most of whom, to this date, have been cured. There’s been an overall response rate of more than 95 percent,” Robert Baiocchi, MD, PhD, says. “It’s a very aggressive disease, and this is a good treatment option for people who don’t want to undergo aggressive chemotherapy."